Propensity Score Matching Analysis Comparing the Efficacy and Steroid Tapering Benefit of Extracorporeal Photopheresis to Best Available Therapy in Third-Line or Beyond Treatment for Chronic GvHD
Source : https://www.sciencedirect.com/science/article/abs/pii/S2666636723015750?via=ihub
Graft-versus host disease (GvHD) is one of the major limitations to allogeneic hematopoietic stem cell transplantation (HCT). While corticosteroids ...
The current study demonstrates superior FFS, OS and steroid tapering efficacy for ECP vs BAT as third-line therapy or beyond in cGvHD patients.
Targeting Hedgehog Signaling with Glasdegib in Patients with Refractory Sclerotic Chronic GVHD: A Report of Two Phase I/II Trials
AbstractPurpose:. Sclerotic chronic GVHD (scGVHD) is characterized by progressive skin fibrosis and frequent refractoriness to available therapies. Aberrant activation of Hedgehog signaling in dermal fibroblasts has been implicated in scGVHD....
Glasdegib demonstrated promising responses in patients with refractory scGVHD, but tolerability was limited by muscle cramping.
Single Centre Retrospective Analysis of Extracorporeal Photopheresis (ECP) Therapy in Patients Heavily Pre-Treated for Chronic Graft-Versus-Host Disease (cGvHD) With Steroid Failure
Source : https://www.sciencedirect.com/science/article/pii/S0145212623006525?via=ihub
Extracorporeal photopheresis (ECP) is recommended as a second- or later-line therapy for chronic GvHD (cGvHD). Benefits include reasonable response wi...
ECP is an effective treatment option for heavily pre-treated cGvHD patients.
We observed asymmetric di-methylation of IDH2 by PRMT1 at arginine 353 promoted IDH2 homodimerization, which enhanced IDH2 activity, further increasing B cell proliferation and antibody production. Collectively, this study provides a rationale for the application of PRMT1 inhibitors in the prevention of aGVHD and cGVHD.
Incidence and Outcome of Atypical Manifestations of Chronic Graft-Versus-Host Disease - Results From a Retrospective Single-Center Analysis
Source : https://www.sciencedirect.com/science/article/abs/pii/S2666636723015555?via=ihub
Chronic graft-versus-host disease (cGvHD) is the leading cause of late non-relapse mortality (NRM) after allogeneic stem cell transplantation (alloHSC...
In summary, atypical cGvHD is more common than previously estimated and has both, similarities with and differences from NIH-defined cGvHD. In particular, the increased NRM and a subset of patients with only atypical cGvHD point to the urgent need to capture these manifestations in cGvHD cohorts, including analysis of treatment outcome.